Investment Analysts’ Weekly Ratings Changes for Exelixis (EXEL)

Several brokerages have updated their recommendations and price targets on shares of Exelixis (NASDAQ: EXEL) in the last few weeks:

  • 9/14/2017 – Exelixis is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $32.00 price target on the stock.
  • 9/12/2017 – Exelixis had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock, up previously from $28.00.
  • 9/10/2017 – Exelixis had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $29.00 price target on the stock.
  • 9/10/2017 – Exelixis had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/7/2017 – Exelixis had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $26.00 price target on the stock.
  • 8/25/2017 – Exelixis was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/14/2017 – Exelixis was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 8/10/2017 – Exelixis had its “outperform” rating reaffirmed by analysts at Cowen and Company.
  • 8/7/2017 – Exelixis was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 8/3/2017 – Exelixis had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $26.00 price target on the stock.
  • 8/3/2017 – Exelixis was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $29.00 price target on the stock, up previously from $26.00.
  • 8/3/2017 – Exelixis had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $29.00 price target on the stock.
  • 7/27/2017 – Exelixis had its “outperform” rating reaffirmed by analysts at William Blair.

Shares of Exelixis, Inc. (NASDAQ:EXEL) opened at 27.92 on Wednesday. Exelixis, Inc. has a 12 month low of $10.04 and a 12 month high of $29.50. The company has a market cap of $8.21 billion, a price-to-earnings ratio of 141.01 and a beta of 1.97. The company’s 50-day moving average price is $27.08 and its 200-day moving average price is $23.49.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. The firm had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) earnings per share. Analysts anticipate that Exelixis, Inc. will post $0.27 EPS for the current year.

In other Exelixis news, VP Patrick J. Haley sold 60,640 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $27.21, for a total value of $1,650,014.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher J. Senner sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total transaction of $2,679,000.00. The disclosure for this sale can be found here. Insiders sold 560,640 shares of company stock worth $15,087,014 over the last three months. 5.10% of the stock is owned by insiders.

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Receive News & Ratings for Exelixis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply